[go: up one dir, main page]

WO2003048195A3 - Nouvelles insulines gluco-dependantes - Google Patents

Nouvelles insulines gluco-dependantes Download PDF

Info

Publication number
WO2003048195A3
WO2003048195A3 PCT/DK2002/000804 DK0200804W WO03048195A3 WO 2003048195 A3 WO2003048195 A3 WO 2003048195A3 DK 0200804 W DK0200804 W DK 0200804W WO 03048195 A3 WO03048195 A3 WO 03048195A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
glucose
derivatives
dependant release
sensing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2002/000804
Other languages
English (en)
Other versions
WO2003048195A2 (fr
Inventor
Thomas Hoeg-Jensen
Svend Havelund
Jan Markussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to EP02781167A priority Critical patent/EP1453860A2/fr
Priority to AU2002349295A priority patent/AU2002349295A1/en
Priority to JP2003549382A priority patent/JP2005526009A/ja
Publication of WO2003048195A2 publication Critical patent/WO2003048195A2/fr
Publication of WO2003048195A3 publication Critical patent/WO2003048195A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des dérivés d'insuline présentant un capteur de glucose incorporé et un fragment polyol, pouvant diffuser de l'insuline à partir d'une injection retard d'un dérivé d'insuline décrit dans l'invention en fonction de la concentration en glucose dans le tissu environnant.
PCT/DK2002/000804 2001-12-02 2002-12-02 Nouvelles insulines gluco-dependantes Ceased WO2003048195A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02781167A EP1453860A2 (fr) 2001-12-02 2002-12-02 Nouvelles insulines gluco-dependantes
AU2002349295A AU2002349295A1 (en) 2001-12-02 2002-12-02 Glucose dependant release of insulin from glucose sensing insulin derivatives
JP2003549382A JP2005526009A (ja) 2001-12-02 2002-12-02 新規グルコース依存性インスリン

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200101784 2001-12-02
DKPA200101784 2001-12-02
US33703301P 2001-12-05 2001-12-05
US60/337,033 2001-12-05

Publications (2)

Publication Number Publication Date
WO2003048195A2 WO2003048195A2 (fr) 2003-06-12
WO2003048195A3 true WO2003048195A3 (fr) 2004-03-25

Family

ID=26069103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000804 Ceased WO2003048195A2 (fr) 2001-12-02 2002-12-02 Nouvelles insulines gluco-dependantes

Country Status (4)

Country Link
EP (1) EP1453860A2 (fr)
JP (1) JP2005526009A (fr)
AU (1) AU2002349295A1 (fr)
WO (1) WO2003048195A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003240437A1 (en) * 2002-06-27 2004-01-19 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
ATE482977T1 (de) * 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
EP2404934A1 (fr) 2006-09-22 2012-01-11 Novo Nordisk A/S Analogues d'insuline résistants à la protéase
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
EP2448962B1 (fr) 2009-06-30 2016-10-19 Novo Nordisk A/S Dérivés d'insuline
TWI507462B (zh) * 2010-01-25 2015-11-11 羅門哈斯電子材料有限公司 包含有含氮化合物之光阻
US9908925B2 (en) 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
EP2836508B1 (fr) 2012-04-11 2016-06-29 Novo Nordisk A/S Formulations à base d'insuline
WO2014093696A2 (fr) * 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Dérivés d'insuline pour le traitement du diabète
WO2014161952A1 (fr) 2013-04-05 2014-10-09 Novo Nordisk A/S Dispositif d'enregistrement de dose destiné à un dispositif d'administration de médicament
EP3055325B1 (fr) 2013-10-07 2018-01-03 Novo Nordisk A/S Nouveau dérivé d'insuline
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
HK1247836A1 (zh) * 2015-03-13 2018-10-05 Case Western Reserve University 含有葡萄糖调节的构象转换器的胰岛素类似物
WO2016179568A1 (fr) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Insulines sensibles au glucose
AU2017272862A1 (en) 2016-06-02 2019-01-17 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
EP3541397A4 (fr) * 2016-11-21 2020-11-04 Case Western Reserve University Analogue d'insuline à action rapide à stabilité améliorée
US11697007B2 (en) 2016-12-05 2023-07-11 North Carolina State University Core-shell microneedle devices and uses thereof
WO2018109162A1 (fr) 2016-12-16 2018-06-21 Novo Nordisk A/S Compositions pharmaceutiques contenant de l'insuline
MA71363A (fr) 2017-11-09 2025-04-30 Novo Nordisk A/S L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose
JP2021504402A (ja) 2017-12-01 2021-02-15 サノフイＳａｎｏｆｉ 薬剤とグルコース感知タンパク質に結合し得る部分との新規のコンジュゲート
EP3781147A4 (fr) * 2018-04-16 2022-04-20 University of Utah Research Foundation Insuline sensible au glucose
CA3131832A1 (fr) * 2019-03-29 2020-10-08 Novo Nordisk A/S Derives d'insuline sensibles au glucose
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
GB2610490A (en) * 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
IL302775A (en) * 2020-11-19 2023-07-01 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
WO2022154055A1 (fr) * 2021-01-13 2022-07-21 地方独立行政法人神奈川県立産業技術総合研究所 Polyglycérol, composition de gel complexe contenant ledit polyglycérol, micro-aiguille d'administration de médicament comprenant ladite composition de gel complexe et procédés pour leur production
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
JP7634756B2 (ja) * 2023-04-24 2025-02-21 ノヴォ ノルディスク アー／エス グルコース感受性インスリン誘導体
KR102802795B1 (ko) * 2023-04-24 2025-05-08 노보 노르디스크 에이/에스 글루코스 민감성 인슐린 유도체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478575A (en) * 1989-10-19 1995-12-26 Nippon Oil & Fats Co., Ltd. Polymers having benzeneboronic acid groups and insulin complexes of same of a sugar response type
WO2000064940A1 (fr) * 1999-04-27 2000-11-02 Eli Lilly And Company Cristaux d'insuline destines a une administration pulmonaire
WO2001092334A1 (fr) * 2000-06-02 2001-12-06 Novo Nordisk A/S Liberation glucose-dependante d'insuline par des derives d'insuline detectant le glucose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478575A (en) * 1989-10-19 1995-12-26 Nippon Oil & Fats Co., Ltd. Polymers having benzeneboronic acid groups and insulin complexes of same of a sugar response type
WO2000064940A1 (fr) * 1999-04-27 2000-11-02 Eli Lilly And Company Cristaux d'insuline destines a une administration pulmonaire
WO2001092334A1 (fr) * 2000-06-02 2001-12-06 Novo Nordisk A/S Liberation glucose-dependante d'insuline par des derives d'insuline detectant le glucose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANNE EGGERT ET AL: "A New Glucose-Selective Fluorescent Bisboronic Acid. First Report of Strong x-Furanose Complexation in Aqueous Solution at Physilogical pH1", J.ORG.CHEM, vol. 64, no. 11, 1999, pages 3846 - 3852, XP002236216 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein

Also Published As

Publication number Publication date
AU2002349295A8 (en) 2003-06-17
JP2005526009A (ja) 2005-09-02
EP1453860A2 (fr) 2004-09-08
WO2003048195A2 (fr) 2003-06-12
AU2002349295A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048195A3 (fr) Nouvelles insulines gluco-dependantes
AU2001263775A1 (en) Glucose dependent release of insulin from glucose sensing insulin derivatives
AU2001251339A1 (en) Optically based transcutaneous blood gas sensor
AU5585899A (en) Cannula tip pressure sensor
AU4063200A (en) Pressure sensing cannula
AU2001285054A1 (en) Subcutaneous infusion cannula
AU2001258845A1 (en) Sensor device, setting device, reading device, and article administration system
AU2002234176A1 (en) Glucose sensor system
AU2001259656A1 (en) Implantable sensor
WO2002018936A3 (fr) Procedes de regulation du niveau de glucose chez un sujet et utilisations de ceux-ci
AU2001239304A1 (en) Implantable analyte sensor
AU2001260130A1 (en) Implantable analyte sensor
AU2001271044A1 (en) Safe retained needle
AU2002366274A1 (en) Needleless hypodermic injection device
EP1293503A4 (fr) Derives de triazole
AU2001293460A1 (en) Medical injection device
AU2001233300A1 (en) Sponsor funded stored value card
MXPA01011872A (es) Derivados de furanona como inhibidores de la catepsina s.
AU2003208316A1 (en) Minimising body weight gain in insulin treatment
EP1272240B8 (fr) Seringue hypodermique
AU2003900366A0 (en) Hypodermic needles and other small diameter components
ZA200107275B (en) Hypodermic injection system.
WO2000056325A3 (fr) Solution d'ibuprofene
AU2002240004A1 (en) Infusion cannula
ZA200500219B (en) Modified bryodin 1 with reduced immunogenicity.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002781167

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003549382

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002781167

Country of ref document: EP